Prolia (denosumab; Amgen/Daiichi Sankyo) is a fully human monoclonal antibody developed by Amgen for the treatment of osteoporosis. Prolia acts by binding to the receptor activator for nuclear factor kappa B ligand (RANKL), preventing activation of its receptor, RANK. The inhibition of this interaction acts to decrease bone resorption, reducing bone turnover and increasing bone mass and strength by inhibition of osteoclastogenesis and osteoclast activity.
LIST OF FIGURES
10 Figure 1: Prolia for osteoporosis – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Prolia for osteoporosis
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Prolia for osteoporosis
LIST OF TABLES
5 Table 1: Prolia drug profile
7 Table 2: Prolia pivotal trial data in osteoporosis
9 Table 3: Prolia late-phase trial data in osteoporosis
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.